Dr Reddy’s Laboratories Ltd Q3 FY26 – ₹8,753 Cr Quarterly Revenue, ₹14.5 EPS, ROCE 22.7%: Generic Giant Having a Mid-Life Crisis
1. At a Glance – Blink and You’ll Miss the Drama
₹96,567 crore market cap. Stock price chilling at ₹1,157, down ~9.5% in the last three months like it’s avoiding eye contact with investors. Trailing P/E of ~17.3 when the industry median is flirting with ~29. ROCE a healthy 22.7%, ROE at 18%, debt-to-equity a polite 0.16 (not zero, but well-behaved).
Latest quarterly numbers? Sales at ₹8,753 crore, up 4.4% YoY, but PAT slipped ~14.4% YoY to ~₹1,190 crore. EPS for the quarter at ₹14.50. Translation: revenue still jogging, profits stopped for water.
Dr Reddy’s today looks like that topper who still scores well but no longer shocks the class. Is this a temporary breather or a sign of generics fatigue? Let’s put on the auditor glasses and dig. Curious already?
2. Introduction – From Generic Gladiator to Corporate Adulting
Dr Reddy’s has been around long enough to see multiple pharma cycles: patent cliffs, USFDA love-hate letters, Russia surprises, COVID miracles, and now… biosimilars, injectables, and niche launches.
Once upon a Dalal Street bedtime story, Dr Reddy’s was the poster child of Indian generics in the US. File ANDAs, win first-to-file, mint money, repeat. That playbook still exists, but margins are no longer falling from the sky.
FY22 revenue mix shows ~83% from Global Generics, ~14% from Pharmaceutical Services & Active Ingredients (PSAI), and a tiny ~2% from proprietary products. The company has deliberately reduced risky bets, sold off non-core assets, and tightened R&D spends from 13% of revenue in FY18 to ~8% by FY22.
Sounds mature. But maturity in pharma often means slower excitement. Investors love adrenaline. Dr Reddy’s is now serving multivitamins. Is that bad? Or just… boring? Let’s see.
3. Business Model – WTF Do They Even Do?
Think of Dr Reddy’s as a pharmaceutical thali 🍛:
Global Generics (Main Sabzi) 400+ generic drugs across nervous system, GI, anti-infectives, etc. US alone contributes ~37% of total revenue. High volume, brutal pricing pressure, regulatory headaches included free.
PSAI – APIs & Services (Protein Portion) One of the largest API manufacturers globally. Filed 139 DMFs worldwide in FY22. This segment quietly supports margins and internal supply chain efficiency.
CPS (Dessert They Sold Off) Contract pharma services were partially divested to focus on core operations. Less distraction, less optionality.
Proprietary & Biosimilars (Masala Papad) Tiny revenue contribution today, but strategically loud. Aurigene works on oncology and inflammation molecules. Biosimilars like denosumab are meant to be the future jackpot.
So yes, Dr Reddy’s sells pills. But the real game is which pill, in which geography, under which regulator. Confused already? Good. That means you’re paying attention.
4. Financials Overview – Numbers Don’t Lie, They Just Smirk
Result Type Detected:Quarterly Results (Q3 FY26). Locked.
